Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 16/20 | 0.74 |
| ▸ | LPAR3 | Q9UBY5 | 12/20 | 0.74 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.40 |
| ▸ | KLRK1 | P26718 | 1/20 | 0.39 |
| ▸ | MICA | Q29983 | 1/20 | 0.39 |
| ▸ | RAET1L | Q5VY80 | 1/20 | 0.39 |
| ▸ | PTGFR | P43088 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16700368 | 0.85 | LPAR1 (1.00) | LPAR1LPAR3 | |
| SCHEMBL16699793 | 0.85 | LPAR1 (1.00) | LPAR1LPAR3 | |
| SCHEMBL16699795 | 0.85 | LPAR1 (1.00) | LPAR1LPAR3 | |
| SCHEMBL14711410 | 0.85 | LPAR1 (0.76) | LPAR1LPAR3 | |
| SCHEMBL16700972 | 0.85 | LPAR1 (0.87) | LPAR1LPAR3 | |
| SCHEMBL16706499 | 0.82 | LPAR1 (1.00) | LPAR1LPAR3 | |
| SCHEMBL24868274 | 0.79 | LPAR1 (0.57) | LPAR1LPAR3 | |
| SCHEMBL30191944 | 0.79 | LPAR1 (0.57) | LPAR1LPAR3 | |
| SCHEMBL25897723 | 0.79 | LPAR1 (0.57) | LPAR1LPAR3 | |
| SCHEMBL30192205 | 0.79 | LPAR1 (0.59) | LPAR1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321738-B2 | N-alkyltriazole compounds as LPAR antagonists | HOFFMAN-LA ROCHE INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-20150133511-A1 | N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2015-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133511-A1 | N-ALKYLTRIAZOLE COMPOUNDS AS LPAR ANTAGONISTS | LPAR1, LPAR2, LPAR3 | LPAR1 1/4885LPAR3 3/4885AKR1C3 542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.